Acne rosacea is an inflammatory skin disease that affects 3% of the US population over 30 years of age and is characterized by erythema, papulopustules and telangiectasia1,2,3. The etiology of this disorder is unknown, although symptoms are exacerbated by factors that trigger innate immune responses, such as the release of cathelicidin antimicrobial peptides4. Here we show that individuals with rosacea express abnormally high levels of cathelicidin in their facial skin and that the proteolytically processed forms of cathelicidin peptides found in rosacea are different from those present in normal individuals. These cathelicidin peptides are a result of a post-translational processing abnormality associated with an increase in stratum corneum tryptic enzyme (SCTE) in the epidermis. In mice, injection of the cathelicidin peptides found in rosacea, addition of SCTE, and increasing protease activity by targeted deletion of the serine protease inhibitor gene Spink5 each increases inflammation in mouse skin. The role of cathelicidin in enabling SCTE-mediated inflammation is verified in mice with a targeted deletion of Camp, the gene encoding cathelicidin. These findings confirm the role of cathelicidin in skin inflammatory responses and suggest an explanation for the pathogenesis of rosacea by demonstrating that an exacerbated innate immune response can reproduce elements of this disease.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Kelly, A.P. Acne and related disorders. in Principles and Practice of Dermatology (eds. Sams, W. & Lynch, P.) 801–818 (Churchill Livingstone, New York, 1996).
Straus, J. Rosacea and acne rosacea. in Dermatology (eds. Orkin, M., Maibach, H. & Dahl, M.) 337–338 (Prentice Hall International Inc., New Jersey, 1991).
Crawford, G.H., Pelle, M.T. & James, W.D. Rosacea: I. Etiology, pathogenesis, and subtype classification. J. Am. Acad. Dermatol. 51, 327–341 quiz 342–344 (2004).
Zanetti, M. The role of cathelicidins in the innate host defenses of mammals. Curr. Issues Mol. Biol. 7, 179–196 (2005).
Zanetti, M. Cathelicidins, multifunctional peptides of the innate immunity. J. Leukoc. Biol. 75, 39–48 (2004).
van Dijk, A., Veldhuizen, E.J., van Asten, A.J. & Haagsman, H.P. CMAP27, a novel chicken cathelicidin-like antimicrobial protein. Vet. Immunol. Immunopathol. 106, 321–327 (2005).
Chang, C.I., Pleguezuelos, O., Zhang, Y.A., Zou, J. & Secombes, C.J. Identification of a novel cathelicidin gene in the rainbow trout, Oncorhynchus mykiss. Infect. Immun. 73, 5053–5064 (2005).
Nizet, V. et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 414, 454–457 (2001).
Rosenberger, C.M., Gallo, R.L. & Finlay, B.B. Interplay between antibacterial effectors: a macrophage antimicrobial peptide impairs intracellular Salmonella replication. Proc. Natl. Acad. Sci. USA 101, 2422–2427 (2004).
Iimura, M. et al. Cathelicidin mediates innate intestinal defense against colonization with epithelial adherent bacterial pathogens. J. Immunol. 174, 4901–4907 (2005).
Howell, M.D. et al. Selective killing of vaccinia virus by LL-37: implications for eczema vaccinatum. J. Immunol. 172, 1763–1767 (2004).
Ong, P.Y. et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. 347, 1151–1160 (2002).
Oppenheim, J.J. & Yang, D. Alarmins: chemotactic activators of immune responses. Curr. Opin. Immunol. 17, 359–365 (2005).
De, Y. et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J. Exp. Med. 192, 1069–1074 (2000)[AG1].
Koczulla, R. et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J. Clin. Invest. 111, 1665–1672 (2003).
Gallo, R.L. et al. Syndecans, cell surface heparan sulfate proteoglycans, are induced by a proline-rich antimicrobial peptide from wounds. Proc. Natl. Acad. Sci. USA 91, 11035–11039 (1994).
Frohm, M. et al. The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J. Biol. Chem. 272, 15258–15263 (1997).
Heilborn, J.D. et al. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J. Invest. Dermatol. 120, 379–389 (2003).
Zaiou, M., Nizet, V. & Gallo, R.L. Antimicrobial and protease inhibitory functions of the human cathelicidin (hCAP18/LL-37) prosequence. J. Invest. Dermatol. 120, 810–816 (2003).
Braff, M.H. et al. Structure-function relationships among human cathelicidin peptides: dissociation of antimicrobial properties from host immunostimulatory activities. J. Immunol. 174, 4271–4278 (2005).
Yamasaki, K. et al. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicdiins in skin. FASEB J. 20, 2068–2080 (2006).
Murakami, M., Lopez-Garcia, B., Braff, M., Dorschner, R.A. & Gallo, R.L. Postsecretory processing generates multiple cathelicidins for enhanced topical antimicrobial defense. J. Immunol. 172, 3070–3077 (2004).
Descargues, P. et al. Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity. Nat. Genet. 37, 56–65 (2005).
Gallo, R.L. et al. Identification of CRAMP, a cathelin-related antimicrobial peptide expressed in the embryonic and adult mouse. J. Biol. Chem. 272, 13088–13093 (1997).
Komatsu, N. et al. Quantification of human tissue kallikreins in the stratum corneum: dependence on age and gender. J. Invest. Dermatol. 125, 1182–1189 (2005).
Dorschner, R.A. et al. Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. J. Invest. Dermatol. 117, 91–97 (2001).
Acharya, M.R., Venitz, J., Figg, W.D. & Sparreboom, A. Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. Drug Resist. Updat. 7, 195–208 (2004).
Hansson, L. et al. Epidermal overexpression of stratum corneum chymotryptic enzyme in mice: a model for chronic itchy dermatitis. J. Invest. Dermatol. 118, 444–449 (2002).
Brinnel, H., Friedel, J., Caputa, M., Cabanac, M. & Grosshans, E. Rosacea: disturbed defense against brain overheating. Arch. Dermatol. Res. 281, 66–72 (1989).
Murakami, M. et al. Cathelicidin anti-microbial peptide expression in sweat, an innate defense system for the skin. J. Invest. Dermatol. 119, 1090–1095 (2002).
We thank B. Cottrell for instructions in SELDI-TOF-MS analysis. This work was supported by the National Institutes of Health (R01-AI052453, R01-AR45676), The National Rosacea Society and a VA Merit Award (R.L.G.); and the Association for Preventive Medicine of Japan (K.Y.).
The authors declare no competing financial interests.
About this article
Cite this article
Yamasaki, K., Di Nardo, A., Bardan, A. et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 13, 975–980 (2007). https://doi.org/10.1038/nm1616
Journal of Investigative Dermatology (2020)
The Journal of Dermatology (2020)
International Journal of Molecular Sciences (2020)
European Journal of Ophthalmology (2020)
Journal of Dermatological Treatment (2020)